Literature DB >> 9858931

Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis.

W Voigt1, S Matsui, M B Yin, W C Burhans, H Minderman, Y M Rustum.   

Abstract

BACKGROUND: SN-38 is the active metabolite of the topoisomerase-I (topo-I) inhibitor Irinotecan (CPT-11). Generally, topo-I inhibitors stabilize the complex between topo-I and DNA which collide with moving DNA replication forks, eventually leading to double stranded DNA damage. Therefore, topo-I inhibitors are regarded as S-phase specific. The present study investigated S-phase dependent and independent effects of SN-38.
MATERIALS AND METHODS: Effects of exposure of A2780 cells to SN-38 (2 hours) were studied by assessing DNA/protein crosslinks, DNA damage and cytogenetic aberrations.
RESULTS: A close correlation (r2 = 0.97) was established between drug-induced DNA/protein crosslinks and double stranded DNA breaks. Cytogenetic analysis revealed near maximum clastogenic effects already evident immediately following 2 hours drug exposure. However, qualitatively, chromatid breaks at 24 hours were different from those at 0 hours, in that at 24 hours they were associated with radial chromosome configurations and sister chromatid exchanges.
CONCLUSION: The data corroborate that the S-phase dependent mechanism of action of topo-I inhibitors is also applicable to SN-38. The cytogenetic data indicate two distinct interactions of SN-38 with DNA: immediate induction of chromatid breaks independent from DNA synthesis, and induction of chromatid breaks associated with radial chromosome configurations dependent on DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858931

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Authors:  Jiuping Ji; Yiping Zhang; Christophe E Redon; William C Reinhold; Alice P Chen; Laura K Fogli; Susan L Holbeck; Ralph E Parchment; Melinda Hollingshead; Joseph E Tomaszewski; Quentin Dudon; Yves Pommier; James H Doroshow; William M Bonner
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

2.  Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Authors:  Alexander Stein; Wieland Voigt; Karin Jordan
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

3.  Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination.

Authors:  Luciana Ferrara; Eric B Kmiec
Journal:  Nucleic Acids Res       Date:  2004-10-05       Impact factor: 16.971

4.  A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.

Authors:  Ricardo J Parker; John P Fruehauf; Rita Mehta; Emese Filka; Timothy Cloughesy
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

5.  Kinetics of γH2AX and phospho-histone H3 following pulse treatment of TK6 cells provides insights into clastogenic activity.

Authors:  Steven M Bryce; Stephen D Dertinger; Jeffrey C Bemis
Journal:  Mutagenesis       Date:  2021-07-07       Impact factor: 2.954

6.  Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.

Authors:  Federica Lopes; Rowena Smith; Sophie Nash; Rod T Mitchell; Norah Spears
Journal:  Mol Hum Reprod       Date:  2016-07-28       Impact factor: 4.025

7.  Injectable SN-38-embedded Polymeric Microparticles Promote Antitumor Efficacy against Malignant Glioma in an Animal Model.

Authors:  Yuan-Yun Tseng; Tao-Chieh Yang; Shu-Mei Chen; Shun-Tai Yang; Ya-Ling Tang; Shih-Jung Liu
Journal:  Pharmaceutics       Date:  2020-05-24       Impact factor: 6.321

8.  Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer.

Authors:  Patrick J Fleming; Sylvia Karpio; Nicholas Lombardo
Journal:  J Adv Pract Oncol       Date:  2021-09-01

9.  Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.

Authors:  S M Harris; P Mistry; C Freathy; J L Brown; P A Charlton
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

10.  Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.

Authors:  Marloes Zoetemelk; George M Ramzy; Magdalena Rausch; Patrycja Nowak-Sliwinska
Journal:  Molecules       Date:  2020-06-04       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.